Observational Study
Copyright ©The Author(s) 2024.
World J Hepatol. Mar 27, 2024; 16(3): 428-438
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.428
Table 1 Comparison of baseline characteristics of cirrhotic patients with refractory ascites palliated with long-term abdominal drain or repeat large volume paracentesis, n (%)
Baseline characteristics
LTAD (n = 30)
LVP (n = 19)
P value
Age, yr (SD)71 (11)66 (12)0.07
Male sex18 (60)15 (79)0.22
Child-Pugh score (IQR)9 (2)9 (2)0.48
Child-Pugh class B/C24/11 (69/31)12/7 (63/37)0.76
Aetiology (MASLD/ArLD/Viral/Other)9/12/2/7 (30/40/7/23)3/10/1/5 (16/53/5/26)0.69
HCC5 (17)4 (21)0.46
Proteins in ascites ≤ 15 g/L14 (47)9 (47)0.76
Prophylactic antibiotics25/311 (81)8/19 (42)0.012
Previous peritonitis2 (7)5 (26)0.86
T2DM12 (40)8 (42)1.00
Use of metformin3 (10)3 (16)0.66
Use of diuretics18 (60)12 (63)1.00
Use of NSBBs13 (43)4 (21)0.13
Use of antihypertensive2 (7)2 (10)0.66
Use of lactulose13 (43)13 (68)0.14
Baseline creatinine (IQR)104 (68)84 (143)0.44
Table 2 Comparative outcomes and safety events by type of ascitic drainage, n (%)
Outcomes
LTAD (n = 30)
LVP (n = 19)
P value
Median survival, d124 (330)297 (438)0.06
Median follow-up (with drain in place/undergoing LVP), d135 (226)80 (239)0.98
Ascites/drain related admissions11 (37)17 (89)0.004
Time to first hospitalisation, (IQR), d44 (93)10 (35)0.002
AKI8 (27)11 (58)0.014
Drain-related complications14 (47)11 (58)0.06
Patients with peritonitis5 (17)5 (26)0.46
Total No. of peritonitis episodes10 (33)5 (26)0.98
Cellulitis4 (13)2 (10)1.00
Site leakage 12 (40)2 (10)0.10
Bleeding of drain site2 (7)1 (5)1.00
Hypotension6 (20)4 (21)0.71